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Mutation analysis of 6 spinocerebellar ataxia (SCA) types in patients from southern Turkey
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Background/aim: Spinocerebellar ataxias (SCAs) are complex clinical and genetically heterogeneous, mostly autosomal dominant
neurodegenerative diseases. At present, more than 30 hereditary SCA types have been associated with different gene mutations. In
this study, the frequency distribution of the 6 SCA types 1, 2, 3, 6, 7, and 17 in the Turkish population was investigated with respect to
clinical features.
Materials and methods: 159 patients who received a diagnosis of SCA and 42 healthy controls from Adana, Mersin, Gaziantep,
Hatay, and Osmaniye provinces were included in the study. DNA samples were isolated from 2 mL blood samples and the number of
trinucleotide repeats (TNRs) for each SCA type was detected using PCR-RFLP technique and sequencing.
Results: Of the 6 SCA types that were studied, 4 types, SCA 1, 3, 7, and 17, were positive and all heterozygous for expansions. SCA types
1 and 17 had higher frequencies, 4.4% and 3.8%, respectively, than SCA types 3 and 7. The clinical data of patients were also evaluated
to correlate with the increased TNR numbers.
Conclusion: This study, being the first mutation record of SCAs in this area, indicated that 9.4% of cases belonged to 4 types, SCA 1, 3,
7, and 17.
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1. Introduction
Spinocerebellar
ataxias
(SCAs)
are
complex
neurodegenerative diseases that are characterized by
ophthalmoplegia, loss of vision, dysarthria, dementia,
and loss of muscle coordination (1–3). SCAs are mostly
dominantly inherited (1). Some types of this complex
disease are starting to be defined with the discovery of
different gene loci causing the syndrome (4). More than
30 types of SCA have been associated with distinct loci
with the most common being types 1–3, 6, and 7 (5). So
far, genes and mutations responsible for 15 of the SCAs
have been identified by genetic studies and for the others,
although association studies by linkage analysis have been
completed, no specific genes and mutations have yet been
identified (6).
Most of the mutations causing SCAs result from
abnormal increases in the number of trinucleotide repeats
(TNRs) (7). The amount of the increase in TNRs is
thought to be related to the severity of the symptoms and
with the age of onset of the disease, although no conclusive
evidence has been found yet (8). At the moment, there is
* Correspondence: hkasap@cu.edu.tr
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no cure for the disease but correct identification of the type
of disease is important for early diagnosis of the syndrome
as it may occur in other family members as well as for the
improvement of patient life quality.
The genes related to these types of ataxias normally
encode a protein called ataxin and the CAG codon encodes
glutamine amino acid. However, the affected gene with the
increased CAG repetitions in the encoding region produces
a mutant protein that contains far more glutamine residues
than usual; therefore, these types of ataxia are classified as
polyglutamine diseases (9). Mutant ataxin protein has a
toxic function causing neurodegeneration (6).
Another complex neurodegenerative disease caused by
trinucleotide expansion mutations that occur in the coding
regions is Friedrich’s ataxia (FA), which is known to have
very similar symptoms to those of SCA. FA patients living
in almost the same geographic area as those of this study
were previously studied by Yilmaz et al. (10).
The SCA types studied here (1, 2, 3, 6, 7, and 17) are
caused by CAG repeat expansion mutations in the coding
regions of the related genes (6). Thus, in this study it is

PAZARCI et al. / Turk J Med Sci
hoped that obtaining genetic information about the
mutation ratios and the correlations among the number
of TNRs, age onset, and severity of symptoms will assist
early diagnosis, treatment, and genetic counseling for the
population studied.
2. Materials and methods
2.1. Subjects and DNA isolation
The patients and control groups studied consisted of
people living in Adana, Mersin, Gaziantep, Hatay, and
Osmaniye provinces (southern Turkey) who presented
to the Çukurova University Medical Faculty Hospital
during 2007–2009; the patient group members presented
to the Neurology and Pediatric Neurology Departments
for various neurological complaints and were diagnosed
as SCA; the control group members came to other
departments for nonneurological complaints. Each
patient or control was informed about the study before
blood sampling and was asked to sign an informed
consent form approved by the Ethics Committee of the
Çukurova University Medical Faculty. Of the patient
group consisting of 159 subjects clinically diagnosed with
SCA and the control group consisting of 42 healthy people,
each individual was separately tested for all 6 types of SCA
genes: ATAXIN1, ATAXIN2, ATAXIN3, CACNA1A,
ATXN7, and TBP. A blood sample of 2 mL was taken from
each patient and control and placed into tubes containing
EDTA; DNA samples were obtained using the salting out
method (11).
2.2. PCR-RFLP and statistical analysis
Information about the complaints of the patients and
other clinical and laboratory results were obtained from
medical records prepared by the specialist neurologists
who examined them. Regions with increased TNRs
were amplified using a standard PCR amplification
protocol (12). The primers used for PCR amplification are
given in Table 1 (13,14).
The lengths of the PCR fragments amplified using
the PCR-RFLP technique were determined using
DNASIZE (15) following a 3% agarose gel run. This
program enabled us first to measure the length of the
product in the original gel run and then to calculate the
increased number of sample TNRs. At first, the expected
bp length of the product was accepted as standard (Table
1), i.e. 308 bp (16,17) for SCA 7 and 203 bp (18,19) for
SCA 17 were subtracted and then divided by 3 to find
the increased TNR numbers. After that, the expected
reference TNR numbers of 10 for SCA 7 (16,17) and 38 for
SCA 17 (18,19) were added to the increased TNR numbers
to find the total TNR numbers.
The relationship between the TNR numbers and
variables such as patient complaints, age, age of disease
onset, and sex were analyzed using SPSS 13.0. Lastly, the

accuracy and validity of the agarose gel measurement
method used here was tested by sequencing the related
DNA regions, especially from the samples having
expanded alleles (Table 2). Dye Cycle Sequence (Applied
Biosystems) agents and a 3130 Genetic Analyzer (Applied
Biosystems) were used for sequencing to determine the
exact numbers of TNRs.
3. Results
For SCA types 1, 2, 3, 6, 7, and 17, the affected genes and
the largest ranges of TNRs for normal, premutational, and
expanded alleles cited to date are shown in Table 1. Each
of the 42 healthy controls and 159 clinically diagnosed
SCA patients was analyzed separately for increases in
TNR numbers to distinguish SCA types 1, 2, 3, 6, 7, and
17. Ranges and averages of TNR numbers in the controls
and patients studied and the relative frequency of the
particular SCA types in all patients and controls are given
in Table 2. When constructing a control group for a SCA
type, people having no expanded allele for the related
SCA type were considered as normal and, in that way, a
SCA type-specific control cohort was assembled. The
total number of a control cohort particular to a SCA type
is supposed to be the sum of the healthy controls plus all
the patients diagnosed as SCA except for the patients of
the SCA type considered; the number of control cohorts
therefore changed between 195 and 201 as the number
of related SCA types were subtracted. Of the 6 SCA
types studied, 4 types (SCA 1,3, 7, and 17) were observed
with some percentages, with two of these (SCA types
1 and 17) having higher frequencies of 4.4% and 3.8%,
respectively, and all 4 types having one allele expanded
(i.e. all were heterozygous). When calculating the average
TNR numbers shown in Table 2, three patients having the
expanded allele at a premutation level were also included;
these patients showed low penetrance and duly had mild
symptoms. The other two types studied, SCA 2 and 6, were
not encountered in the patients and none of the SCA types
were found in the healthy controls (Table 2).
The primary complaints of patients are noted in Table
3. The age of onset of SCA in the patients ranged between 3
and 40 years old and the rate of consanguineous marriage
was found to be considerably higher for SCA types 1 and
7 (Table 3).
4. Discussion
Repetitive DNA regions account for nearly 50% of the
human genome (20) and changes in the repetitive DNA
regions are thought to contribute to the diversity of many
species during evolution (21). Mammals have developed
various systems in order to prevent changes in the repeat
numbers that can be harmful when a critical threshold
value is exceeded for the repeat numbers. McMurray (22)
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ATXN7

SCA 7 (13,16,17)

SCA 17 (13,18,19) TBP

CACNA1A CACGTGTCCTATTCCCCTGTGATCC TGGGTACCTCCGAGGGCCGCTGGTG 141 (13)

SCA 6 (13,14)

GACCCCACAGCCTATTCAGA

TGTTACATTGTAGGAGCGGAA

CCAGTGACTACTTTGATTCG

TTGACTGCTGAACGGCTGCA

CACGACTGTCCCAGCATCACTT

TGGCCTTTCACATGGATGTGAA

203 (38)

308 (10)

202 (12)

130 (23)

ATAXIN3

CGGGCTTGCGGACATTGG

SCA 3 (13,14)

GGGCCCCTCACCATGTCG

212 (29)

ATAXIN2

AACTGGAAATGTGGACGTAC

25–42

<17

4–20

12–44

16–30

6–36

43–48

17–36

–

45–65

31–34

37–42

49–66

37–460

21–27

66–80

35–59

43–81

Expected size of PCR Reference TNR ranges
product (expected
Normal Pre-mutation Expanded
TNR number)

SCA 2 (13,14)

CAACATGGGCAGTCTGAG

Reverse primer
(5’ → 3’)

ATAXIN1

Forward primer
(5’ → 3’)

SCA 1 (13,14)

Affected
gene

Table 1. Affected genes, primers used for PCR amplification, expected amplification length, and reference TNR ranges for SCA types 1, 2, 3, 6, 7, and 17.
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Table 2. Ranges of TNR numbers in controls (n = 42) and patients (n = 159) studied and relative frequency of SCA types in patients.
TNR numbers (means ± SD)

n

Frequency of
SCA type

Control

Patients

Control Patients

All alleles

Normal allele

Expanded allele

SCA 1

194

7

10–33 (28.2 ± 2.3)

26–33 (29.7 ± 3.0)

43–58 (49.0 ± 5.5)

4.4%

SCA 2

201

0

20–28 (23.5 ± 1.8)

–

–

–

SCA 3

200

1

13–36 (16.3 ± 2.8)

18 (18.0 ± 0.0)

72 (72.0 ± 0.0)

0.6%

SCA 6

201

0

8–18 (12.7 ± 1.3)

–

–

–

SCA 7

200

1

9–17 (12.9 ± 2.4)

17 (17.0 ± 0.0)

77 (77.0 ± 0.0)

0.6%

SCA 17

195

30–42 (36.5 ± 3.4)

30–38 (32.8 ± 2.8)

45–63 (53.5 ± 8.0)

3.8%

Table 3. Clinical data of patients who had one of the alleles expanded for the related SCA type.
n

Age at examination

Age at onset

Consanguineous
marriage rate

Primary
complaint

SCA 1

7

5–50

7–40

57.1% (n = 4)

Gait disorders

SCA 3

1

39

12

0% (n = 0)

Imbalance

SCA 7

1

5

3

100% (n = 1)

Loss of vision

SCA 17

6

3–44

1–36

0% (n = 0)

Imbalance

stated that for repeat numbers over 25–40 in the coding
region of the gene and 55–200 in the noncoding region,
simple TNR repeats become unstable and override the
mechanisms that prevent the increase in TNR numbers
and are prone to increase during an individual’s life and in
parent–child transitions.
Expansion mutations in the glutamine coding regions
of these genes result in spinocerebellar ataxia because
the mutant protein gains a new function as a result of
polyglutamine increase (23), as is probably the case in
the SCA type 1, 2, 3, 6, 7, and 17 gene regions examined
in our study. Although it is still unclear, there are some
opinions explaining how the increased polyglutamine
in proteins causes ataxia. According to Gatchel and
Zoghbi (24), a polyglutamine increase causes production
of an abnormal toxic protein that builds up within the cell
since the cell protein homeostasis is impaired. In sensitive
cells like neurons, this has many harmful consequences
such as abnormal function of organelles, defects in axonal
conductivity, and defects in synaptic activity. According to
Williams and Paulson (25), a polyglutamine increase also
has an impact on the quality control mechanisms of the
proteins and triggers the build-up of misfolded proteins
in the cell. Although these and other similar views put
forward are not conclusive, they all share the common idea
of toxic effects of a polyglutamine increase in proteins.

It is known that the average TNR numbers vary
according to geographical region and race. In this study,
the average TNR numbers in genes with SCA types 1, 2,
3, 6, 7, and 17 and the frequency of each type relative to
all SCA patients studied have been recorded for the first
time for the Çukurova population of Turkey. To determine
the TNR numbers, we used PCR-RFLP combined with
DNASIZE (15). This fast and easy method was confirmed
by the sequencing data of related genes as an adequate
method since no differences were found between the results
of the agarose gel electrophoresis and the sequencing.
Other clinical data of patients such as age of
onset, mental retardation state, primary complaints,
consanguineous marriage status, sex, and paresis state
were also evaluated to correlate with the increased TNR
numbers, but no statistically significant results were
obtained, probably due to the small number of patients
studied. Age of disease onset can vary from infancy to
the age of 70; in our study it varied from 3 to 40 years of
age and, as is generally accepted by many authors, age of
disease onset is inversely correlated to the TNR numbers
and patients with early onset are more likely to receive their
TNR regions via transmission from their parents (26,27).
It was also observed that the degeneration progresses
much faster in patients with early onset (6). Several
studies showed (28–30) that in SCAs with early onset in
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childhood, the affected allele is transmitted to the child
mostly from the father, and according to David et al. (31),
the TNR numbers in the sperm cells of SCA patients
are significantly higher than the TNR numbers in blood
cells. It may also be noteworthy to state our observation
on the patients with consanguineously married parents,
whose alleles, even the normal alleles, tend to have higher
averages of TNR numbers than the controls (Table 2).
However, this assumption could not be examined in detail
due to the lack of parental blood samples.

It appears that this study includes the first mutation
records of SCAs presenting a relative prevalence of 6
SCA types in 6 provinces of southern Turkey. The study
indicates that 9.4% of cases belonged to 4 types: SCA 1, 3,
7, and 17.
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